Skip to main content

Advertisement

SpringerLink
Log in

The optimal TSH level necessary for successful radioiodine ablation of differentiated thyroid carcinoma, as well as the time to reach this level, is a work in progress

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Piccardo A, Puntoni M, Ferrarazzo G, Foppiani L, Bottoni G, Altrinetti V, et al. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients? Eur J Nucl Med Mol Imaging. 2018; https://doi.org/10.1007/s00259-018-3955-x.

  2. Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol. 1977;50:799–807.

    Article  PubMed  CAS  Google Scholar 

  3. Vrachimis A, Rirmann B, Mäder U, Reiners C, Verburg FA. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. Eur J Nucl Med Mil Imaging. 2016;43:224–31.

    Article  CAS  Google Scholar 

  4. Hasbek Z, Turgut B. Is very high thyroid stimulating hormone level required in differentiated thyroid cancer for ablation success? Mol Imaging Radionucl Ther. 2016;25:79–84.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zhao T, Liang J, Guo Z, Li T, Lin Y. In patients with low- to intermediate-risk thyroid cancer, a preablative thyrotropin level of 30 μIU/mL is not adequate to achieve better response to 133I therapy. Clin Nucl Med. 2016;41:454–8.

    Article  PubMed  Google Scholar 

  6. Lawal IO, Nyakale NE, Harry LM, Lengana T, Mokgoro NP, Vorster M, et al. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. Nucl Med Commun. 2017;38:222–7.

    Article  PubMed  CAS  Google Scholar 

  7. Verburg FA, Mäder U, Grille I, Visser TJ, Peeters RP, Smit JW, et al. The thyroid axis ‘setpoint’ are significantly altered after long-term suppressive LT4 therapy. Horm Metab Res. 2014;46:794–9.

    Article  PubMed  CAS  Google Scholar 

  8. Hoermann R, Midgley JE, Giacobino A, Eckl WA, Wahl HG, Dietrich JW, et al. Homeostatic equilibria between free thyroid hormones and pituitary thyrotropin are modulated by various influences including age, body mass index and treatment.

  9. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Private Bag X169, Pretoria, 0001, South Africa

    Ismaheel O. Lawal, Mariza Vorster, Alfred O. Ankrah & Mike M. Sathekge

  2. Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    Alfred O. Ankrah

Authors
  1. Ismaheel O. Lawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariza Vorster
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alfred O. Ankrah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mike M. Sathekge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mike M. Sathekge.

Ethics declarations

Conflict of interest

The authors declare that they have no financial or non-financial competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lawal, I.O., Vorster, M., Ankrah, A.O. et al. The optimal TSH level necessary for successful radioiodine ablation of differentiated thyroid carcinoma, as well as the time to reach this level, is a work in progress. Eur J Nucl Med Mol Imaging 45, 1270–1271 (2018). https://doi.org/10.1007/s00259-018-3999-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-018-3999-y

Search

Navigation